Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis

被引：0

作者：

Hauser, S. ^{[1
]}

Kappos, L. ^{[2
]}

Montalban, X. ^{[3
,4
]}

Craveiro, L. ^{[5
]}

Hughes, R. ^{[5
]}

McNamara, J. ^{[6
]}

Pradhan, A. ^{[7
]}

Wormser, D. ^{[5
]}

Koendgen, H. ^{[5
]}

Wolinsky, J. S. ^{[8
]}

机构：

[1] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA

[2] Univ Basel, Univ Hosp Basel, Dept Neurol, Basel, Switzerland

[3] Univ Toronto, Dept Neurol, Div Neurol, Toronto, ON, Canada

[4] Vall dHebron Univ Hosp, Dept Neurol, Barcelona, Spain

[5] F Hoffmann La Roche Ltd, Basel, Switzerland

[6] John McNamara Consulting Ltd, Cambridge, England

[7] Genentech Inc, San Francisco, CA 94080 USA

[8] Univ Texas Hlth Sci Ctr Houston UTHlth, McGovern Med Sch, Dept Neurol, Houston, TX USA

来源：

关键词：

D O I：

10.1016/j.jns.2019.10.313

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

WCN19-1889

引用

页数：1